We recently contacted all stakeholders for the appraisal of Ozanimod for treating moderate to severe ulcerative colitis [ID3841] regarding a delay to this topic for operational reasons.
Ozanimod for treating moderate to severe ulcerative colitis has now been rescheduled into the work programme and the appraisal is due to start late October 2021 and will be discussed at committee in mid July 2022.
The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.